Erratum: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma (Oncogene (2012) 31 (4859-4867) DOI: 10.1038/onc.2011.647);Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

Oncogene

Volumn 31, Issue 46, 2012, Pages 4859-4867

  Carpenter, E L ^a   Haglund, E A ^a   MacE, E M ^a   Deng, D ^a   Martinez, D ^a   Wood, A C ^a   Chow, A K ^a   Weiser, D A ^a   Belcastro, L T ^a   Winter, C ^a   Bresler, S C ^b   Asgharzadeh, S ^c   Seeger, R C ^c   Zhao, H ^a   Guo, R ^a   Christensen, J G ^d   Orange, J S ^b   Pawel, B R ^a   Lemmon, M A ^a   Mosse Y P ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

anaplastic lymphoma kinase; immunotherapy; Neuroblastoma; receptor tyrosine kinase

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE ANTIBODY; ANTIGEN; CRIZOTINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 30; MONOCLONAL ANTIBODY 49; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL SURFACE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; SENSITIZATION;

EID: 84869502105     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.208     Document Type: Erratum

References (57)

1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284. (Pubitemid 24107549)
2. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203. (Pubitemid 350235027)
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566. (Pubitemid 47206930)
4. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C et al. (2006) Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 12:7104-7112. (Pubitemid 44890638)
5. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ (1999) Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 59:2776-2780. (Pubitemid 29283106)
6. Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A et al. (2002) Activation of anaplastic lymphoma kinase is responsible for hyperphosphoryla-tion of ShcC in neuroblastoma cell lines. Oncogene 21:5823-5834. (Pubitemid 35007232)
7. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362:2202-2211.
8. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M et al. (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28:2625-2634.
9. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C et al. (2007) Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2: e255.
10. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935.
11. Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V et al. (2011) The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 30:2017-2025.
12. George R, Attiyeh E, Li S, Moreau L, Neuberg D, Li C et al. (2007) Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2: e255.
13. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R (2005) Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167:213-222. (Pubitemid 40884782)
14. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM et al. (2010) Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. [Meta-Analysis Research Support, Non-US Government] 16:4353-4362.
15. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M et al. (2009) Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69:7338-7346.
16. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28-39.
17. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317-327.
18. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med (Review) 357:39-51. (Pubitemid 47026733)
19. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T et al. (2007) Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-1561. (Pubitemid 46450447)
20. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. [Research Support, NIH, Extramural Research Support, Non-US Government]. 119:3000-3010.
21. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K et al. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. [Research Support, Non-US Government]. 28:803-814.
22. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:6213-6221. (Pubitemid 43080044)
23. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med [Clinical Trial, Phase I Multicenter Study Research Support, NIH, Extramural Research Support, Non-US Government]. 363:1693-1703.
24. Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS et al. (2011) Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3:108ra14.
25. George RE, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978.
26. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L et al. (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. [Research Support, NIH, Extramural]. 70:10038-10043.
27. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18:73-79. (Pubitemid 351694445)
28. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739.
29. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L et al. (2010) The neuroblastoma associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK translocated cancers. Cancer Res 70:10038-10043.
30. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F et al. (2010) Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 28:2331-2338.
31. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. [Multicenter Study Randomized Controlled Trial Research Support, NIH, Extramural Research Support, US Government, PHS]. 363:1324-1334.
32. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T et al. (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14:439-449. (Pubitemid 27087107)
33. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D et al. (2006) Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66:6050-6062.
34. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J et al. (2005) Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 280:26039-26048. (Pubitemid 41022195)
35. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK et al. (1990) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. [Research Support, Non-US Government Research Support, US Government, PHS]. 50:5234-5239. (Pubitemid 20302968)
36. Bougherara H, Subra F, Crepin R, Tauc P, Auclair C, Poul MA (2009) The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 7:1525-1533.
37. Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP et al. (2008) KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res 14:2285-2294. (Pubitemid 351551059)
38. Bougherara H, Subra F, Crepin R, Tauc P, Auclair C, Poul MA (2009) The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 7:1525-1533.
39. Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP et al. (2008) KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res 14:2285-2294. (Pubitemid 351551059)
40. Hobbie WL, Moshang T, Carlson CA, Goldmuntz E, Sacks N, Goldfarb SB et al. (2008) Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 51:679-683.
41. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT et al. (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582. (Pubitemid 44547808)
42. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334.
43. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744.
44. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M et al. (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914. (Pubitemid 30106623)
45. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243. (Pubitemid 32591441)
46. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137. (Pubitemid 33674041)
47. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974.
48. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970.
49. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM et al. (2010) Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16:4353-4362.
50. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA et al. (2003) Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100:15871-15876. (Pubitemid 38021082)
51. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639. (Pubitemid 43259947)
52. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J et al. (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10:6487-6501. (Pubitemid 39346544)
53. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-3010.
54. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525. (Pubitemid 16052256)
55. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R et al. (2005) Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327-2336. (Pubitemid 40490194)
56. Hughes B (2010) Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov 9:665-667.
57. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J et al. (2005) Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem. [Research Support, Non-US Government]. 280:26039-26048. (Pubitemid 41022195)